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A Novel Therapeutic Strategy Improves Functional Recovery After MCAo 
Stroke in Rats 
Ludmila Belayev, Larissa Khoutorova, Karen L Zhao, Fang M Zuo, Andrew Salzman, lnotek, 
Beverly, MA; Allen W Davidoff, Alan F Moore, Stem Cell Therapeutics Corp, Calgary, 
Canada; Steven C Cramer, Univ of California, Irvine, Irvine, CA 
INTRODUCTION: Human chorionic gonadotropin (hCG) and erythropoietin (EPO) have been 
postulated to contribute to neuroprotection and neuroregeneration by influencing endogenous 
adult neural stem cells. The current study tested the hypothesis that administration of this two 
compound regimen, initiated 24 hours after MCAo stroke, improves long-term behavioral 
outcome. METHODS: Long-Evans rats received 90 min MCAo by retrograde insertion of an 
intraluminal suture coated with poly-L-lysine. At 24 h from MCAo onset, 46 rats were 
randomized into 4 treatment groups in a double-blinded manner: hCG+EPO (3 IM doses hCG 
at 300 IU/kg over 5 days, followed by 3 IV doses EPOGEN at 1440 IU/kg over 3 days), 
hCG+saline in same schedule, saline+EPO in same schedule, or neither drug (saline+saline). 
Primary endpoint was Composite Neurological Score (0-12 points, O=normal), measured 60 
min into occlusion, then at 1 h post-infarct, 24 h post-infarct, and a total of 11 times until 12 
weeks post-infarct. RESULTS: Body and cranial temperature showed no significant group 
differences between groups. The Composite Neurological Score was different over time across 
treatment groups (p<0.056, repeated measures ANOVA time X treatment group). Pairwise 
testing of groups found that the hCG+EPO group had significanUy lower scores at 8/10 
post-stroke time points as compared to saline+saline. The hCG+EPO group scores were lower 
than scores in the single-drug (hCG+saline and saline+EPO) groups in all but one instance but 
significanUy so at only 2 time points. The 2 single-drug treatment arms did not significanUy 
differ at any time point Infarct volume (estimated at Bregma -0.92) in the hCG+EPO group (25 
+/- 18 % of non-stroke hemisphere, mean +/- SD) was reduced as compared to 
saline+saline (46 +/- 27%, p < 0.04), saline+EPO (45 +/- 27%, p < 0.06), and hCG+saline 
(47 + /- 25%, p < 0.04) groups. CONCLUSION: The current therapeutic strategy improved 
behavioral outcome and preserved brain tissue with a time window of 24 hours after stroke 
onset Extensive human experience exists for both hCG and EPO, suggesting high potential for 
translation into studies of acute human stroke. 
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